Executive Management

Jennifer Bath is the CEO and President of MindWalk. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

R. Scott Areglado is the Chief Financial Officer (CFO) at MindWalk. Scott has more than 30 years of experience in finance and accounting with over 15 years experience in healthcare companies. From 2021 to 2023, Scott served as the CFO at BrainsWay, a global medical device leader in interventional psychiatry. Prior to BrainsWay, Scott served as the CFO at iCAD Inc., a medical technology company specializing in AI-driven cancer detection and therapy solutions. Prior to his appointment as CFO, he served as iCAD’s Vice President and Corporate Controller. From 2005 to 2010, Scottserved as Vice President and Controller at AMICAS, Inc., a Nasdaq-listed image and information management solutions company serving the healthcare industry, where he led financial statement preparation and accounting operations for the company leading to the successful acquisition by Merge Healthcare.

Scott received an MBA from the Franklin W. Olin Graduate School of Business at Babson College (Wellesley, Massachusetts) and a BBA degree in Accounting from the University of Massachusetts, Amherst.

Dr. Thomas Lynch serves as the Chief Business Officer at MindWalk. He earned his Ph.D. in Biochemistry at the University of Illinois with a focus on site-specific protein–nucleic acid recognition. Following his doctoral studies, he completed a postdoctoral fellowship funded by the National Cancer Institute at the University of Chicago, where he investigated crystal atomic structures of macromolecules involved in DNA repair. 

Throughout his career, Dr. Lynch has held leadership roles spanning both scientific and commercial domains, particularly within omics software and contract development and manufacturing organizations. At Aldevron, he built and led multiple teams including Technical Sales & Scientific Support, Client Services, and Global Sales, where he consistently drove revenue growth by expanding strategic accounts, launching market-aligned products and services, and cultivating long-term client partnerships to support sustainable business development. 

Dr. Lynch also has been an active advocate for the biohealth sector, serving on the Board of BioForward to promote collaboration, education, and legislative support across Wisconsin’s biotechnology landscape. 

Ingrid Brands is the Chief Innovation and Strategy Officer of MindWalk, with over two decades in management and senior research roles. She has made significant contributions to the field of medicine and neurorehabilitation. 

Throughout her career, Dr. Brands has pioneered innovative approaches in neuropsychological rehabilitation, enhancing the care provided to patients with acquired brain injuries. She has held respected research positions at esteemed institutions such as Libra Revalidatie & Audiologie and the Department of Rehabilitation at Erasmus University. 

Dr. Brands holds a Ph.D. in neurorehabilitation from the University of Maastricht and graduated with distinction from the University of Leuven, specializing in Physical Medicine and Rehabilitation (PM&R). Her commitment to advancing the field is evident in her academic achievements and active involvement in professional committees. 

Under Dr. Brands' leadership, MindWalk formerly IPA and its subsidiary BioStrand continue to evolve, utilizing cutting-edge research and technology to drive advancements in genetic research. Her dedication to innovation and patient care serves as the driving force behind MindWalk's achievements. 

Dirk Van Hyfte is the Chief Technology Officer of MindWalk. With a degree in Medicine and specialization as a Psychiatrist from the prestigious University of Leuven in Belgium, Dirk's expertise extends beyond the realms of technology and business.

As a serial entrepreneur, Dirk has already made significant contributions to the field, with several of his groundbreaking ideas earning him patents. Notably, his remarkable achievement, iKnow, caught the attention of IT provider InterSystems, leading to its acquisition in 2010.

In addition to his entrepreneurial ventures, Dirk serves as a Bio-Medical Advisor, seamlessly blending his medical, AI-analytics, technological, and business acumen. He leverages his profound understanding of medical artificial intelligence, having obtained a PhD in the field from Nijmegen University in the Netherlands.

Dirk’s leadership brings a unique combination of healthcare systems knowledge and AI-driven strategy, positioning MindWalk at the forefront of industry innovation.

Frédéric Chabot is the Head of Corporate Development at MindWalk, focusing on M&A, strategic partnerships, and corporate initiatives. He began working with MindWalk in 2017, contributing in various roles before assuming his current position. With over 26 years of experience in finance and corporate strategy, he navigates biotech investments and market expansion.

Previously, he served as an International Liaison at Contact Financial, an advisory firm specializing in capital raising and investor relations for TSX and TSX-V listed companies. Over nine years, he worked on investor awareness programs and fundraising initiatives, supporting startups and early-stage companies.

Kari Graber serves as the Vice President of Commercial Services for MindWalk, and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.